CDLQI Scores range from 0 to 30. Lower scores indicate better health‐related quality of life. Calculations are based on the change from baseline to week 12 in both groups · people with paediatric psoriasis
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for ketoconazole showed no clear difference in proportion of participants with complete cure compared with griseofulvin (low certainty).
2 findings from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for fluconazole showed no clear difference in the proportion of participants with complete cure compared with terbinafine (low certainty).
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for fluconazole showed no clear difference in proportion of participants with complete cure compared with itraconazole (low certainty).
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton and Microsporum
It is very uncertain whether complete cure for itraconazole changes proportion of participants with complete cure compared with griseofulvin (very low certainty).
1 finding from 1 review
Proportion of participants with complete cure · children infected with Trichophyton
Complete cure for itraconazole showed no clear difference in proportion of participants with complete cure compared with terbinafine (low certainty).
1 finding from 1 review
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review
Quality of life (QoL) ‐ not measured · psoriasis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
It is very uncertain whether FAE changes common nuisance AEs (not leading to treatment discontinuation) compared with MTX (very low certainty).
1 finding from 1 review
PASI 50 · psoriasis
It is very uncertain whether FAE changes PASI 50 compared with MTX (very low certainty).
1 finding from 1 review
Percentage of participants reaching PASI 75 · psoriasis
It is very uncertain whether FAE changes PASI 75 compared with MTX (very low certainty).
1 finding from 1 review
PASI 90 · psoriasis
It is very uncertain whether FAE changes PASI 90 compared with MTX (very low certainty).
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
1 finding from 1 review
QoL · psoriasis
1 finding from 1 review
Common nuisance AEs (not leading to treatment discontinuation) · psoriasis
FAE probably leads to higher common nuisance AEs (not leading to treatment discontinuation) compared with placebo (moderate certainty).
1 finding from 1 review
PASI 50 · psoriasis
FAE may leads to higher PASI 50 compared with placebo (low certainty).
1 finding from 1 review
Percentage of participants reaching PASI 75 · psoriasis
1 finding from 1 review
PASI 90 ‐ not measured · psoriasis
1 finding from 1 review
PASI score (scale range from 0 to 72 (higher score indicates more severe psoriasis)) · psoriasis
1 finding from 1 review
Withdrawals due to adverse events · psoriasis
It is very uncertain whether FAE changes AEs leading to treatment discontinuation compared with MTX (very low certainty).
1 finding from 1 review